Clinical trial • Phase I • Oncology
JNJ-87704916 for Advanced solid tumors
Phase I trial of JNJ-87704916 for Advanced solid tumors. 58 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Advanced solid tumors
- Trial Stage
- Phase I
- Drug Modality
- Gene therapy
Key dates
- Initial CTIS Submission Date
- 24-11-2023
- First CTIS Authorization Date
- 25-03-2024
Trial design
Phase I trial across 4 sites in Spain, France.
- Target Sample Size
- 58
Eligibility
Recruits 58 Vulnerable population not selected; no consent or assent handling described in the available record..
- Vulnerable Population
- Vulnerable population not selected; no consent or assent handling described in the available record.
Recruitment
- Planned Sample Size
- 58
- Recruitment Window Months
- 97
Geography
- Total Number Of Sites
- 4
- Total Number Of Participants
- 38
Spain
- Earliest CTIS Part Ii Submission Date
- 13-12-2023
- Latest Decision Or Authorization Date
- 24-02-2026
- Processing Time Days
- 804
- Number Of Sites
- 3
- Number Of Participants
- 19
Sites
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Medical Oncology
- Principal Investigator Name
- Enriqueta Felip
- Principal Investigator Email
- efelip@vhio.net
- Contact Person Name
- Enriqueta Felip
- Contact Person Email
- efelip@vhio.net
- Site Name
- Hospital Universitario Hm Sanchinarro
- Department Name
- Medical Oncology
- Principal Investigator Name
- Emiliano Calvo
- Principal Investigator Email
- emiliano.calvo@startmadrid.com
- Contact Person Name
- Emiliano Calvo
- Contact Person Email
- emiliano.calvo@startmadrid.com
- Site Name
- Hospital Universitario Fundacion Jimenez Diaz
- Department Name
- Medical Oncology
- Principal Investigator Name
- Victor Moreno
- Principal Investigator Email
- victor.moreno@startmadrid.com
- Contact Person Name
- Victor Moreno
- Contact Person Email
- victor.moreno@startmadrid.com
France
- Earliest CTIS Part Ii Submission Date
- 22-01-2024
- Latest Decision Or Authorization Date
- 05-03-2026
- Processing Time Days
- 773
- Number Of Sites
- 1
- Number Of Participants
- 19
Sites
- Site Name
- Institut Gustave Roussy
- Department Name
- DITEP
- Principal Investigator Name
- Rastilav BAHLEDA
- Principal Investigator Email
- Rastilav.BAHLEDA@gustaveroussy.fr
- Contact Person Name
- Rastilav BAHLEDA
- Contact Person Email
- Rastilav.BAHLEDA@gustaveroussy.fr
Sponsor
Primary sponsor
- Full Name
- Johnson And Johnson Enterprise Innovation Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- JNJ-87704916
- Modality
- Gene therapy
- Routes Of Administration
- Intratumoural injection
- Route
- Intratumoural
- Authorisation Status
- Investigational
Related trials
Other published trials that may interest you.